Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

High cancer mortality for US-born Latinos: evidence from California and Texas

  • Paulo S. Pinheiro1Email author,
  • Karen E. Callahan1,
  • Scarlett Lin Gomez2,
  • Rafael Marcos-Gragera3,
  • Taylor R. Cobb1,
  • Aina Roca-Barcelo3 and
  • Amelie G. Ramirez4
BMC Cancer201717:478

https://doi.org/10.1186/s12885-017-3469-0

Received: 16 November 2016

Accepted: 2 July 2017

Published: 11 July 2017

Abstract

Background

Latinos born in the US, 36 million, comprise 65% of all US Latinos. Yet their cancer experience is nearly always analyzed together with their foreign-born counterparts, 19 million, who constitute a steady influx of truly lower-risk populations from abroad. To highlight specific cancer vulnerabilities for US-born Latinos, we compare their cancer mortality to the majority non-Latino white (NLW) population, foreign-born Latinos, and non-Latino blacks.

Methods

We analyzed 465,751 cancer deaths from 2008 to 2012 occurring among residents of California and Texas, the two most populous states, accounting for 47% of US Latinos. This cross-sectional analysis, based on granular data obtained from death certificates on cause of death, age, race, ethnicity and birthplace, makes use of normal standardization techniques and negative binomial regression models.

Results

While Latinos overall have lower all-cancers-combined mortality rates than NLWs, these numbers were largely driven by low rates among the foreign born while mortality rates for US-born Latinos approach those of NLWs. Among Texas males, rates were 210 per 100,000 for NLWs and 166 for Latinos combined, but 201 per 100,000 for US-born Latinos and 125 for foreign-born Latinos. Compared to NLWs, US-born Latino males in California had mortality rate ratios of 2.83 (95% CI: 2.52–3.18) for liver cancer, 1.44 (95% CI: 1.30–1.61) for kidney cancer, and 1.25 (95% CI: 1.17–1.34) for colorectal cancer (CRC). Texas results showed a similar site-specific pattern.

Conclusions

Specific cancer patterns for US-born Latinos, who have relatively high cancer mortality, similar overall to NLWs, are masked by aggregation of all Latinos, US-born and foreign-born. While NLWs had high mortality for lung cancer, US-born Latinos had high mortality for liver, kidney and male colorectal cancers. HCV testing and reinforcement of the need for CRC screening should be a priority in this specific and understudied population. The unprecedented proximity of overall rates between NLWs and US-born Latino populations runs counter to the prevailing narrative of Latinos having significantly lower cancer risk and mortality. Birthplace data are critical in detecting meaningful differences among Latinos; these findings merit not only clinical but also public health attention.

Keywords

Cancer Hispanics Latinos Mortality Nativity Birthplace Mexican Texas California Immigrants

Background

Cancer accounts for 22% of all deaths among Latinos in the United States (US), a population of 55 million [1, 2]. Yet, Latinos suffer a lower burden of cancer compared to both non-Latino black (NLB) and non-Latino white (NLW) populations, including lower incidence for almost all cancers except gall bladder and infection-related cancers: cervix, liver and stomach [1, 3]. Because overall incidence is lower among Latinos, overall cancer mortality tends to also be lower [1, 4]. These observed advantages may be partially due to the Healthy Immigrant Effect, whereby low incidence and mortality are the result of a steady immigrant influx of lower-risk populations [5, 6].

Acculturation, the complex process by which members of a foreign-born minority population adapt to traits from a prevailing majority [7], has been shown to change several important risk factors for cancer [8, 9], including increased prevalence of tobacco smoking, obesity, metabolic syndrome, diabetes, and hepatitis C virus infection with longer time spent in the US [9]. Consequently, the more acculturated US-born Latinos may be at higher risk for cancer.

Several studies that examined overall cancer mortality by birthplace found higher rates for US-born populations compared to their foreign-born counterparts [1013]. Thus, aggregating cancer rates for any US minority population with significant immigrant proportions, whether Latino, Asian, or Black, may obscure important differences. Moreover, for the whole US, or within each state, the relative weight of the foreign-born population in each racial or ethnic group modifies that group’s observed cancer patterns. For example, while the foreign-born proportion of Blacks in the US is low overall, states such as Florida and New York, with relatively high proportions of Black Caribbean immigrants, have lower cancer mortality among Blacks than the US average [13].

For Latinos, detailed mortality analyses by cancer site according to birthplace are not available. We address this data gap and examine cancer mortality data from California (CA) and Texas (TX), the two states with the largest Latino populations in the US, 14 and 9.5 million respectively, comprising 47% of all US Latinos in 2010 [2]. By comparing cancer mortality in Latinos stratified by birthplace with NLWs and NLBs, we aim to provide a detailed description of cancer outcomes, particularly highlighting differences between two distinct Latino populations: those 36 million (65%) that are US-born, and the 19 million (35%) that are foreign-born [14]. This information will be valuable to health policy makers tasked with reducing disparities and monitoring the health outcomes of this burgeoning US minority population.

Methods

Mortality data for 5 years, January 1, 2008 through December 31, 2012, were obtained from the California Department of Health Center for Health Statistics and Informatics and the Texas Department of State Health Services. Among the resident cases in each state, we analyzed 20 common causes of cancer deaths as well as all-sites-combined cancer which included all cases of malignant cancers. Cancer site was coded according to the International Statistical Classification of Diseases 10th revision. Ethnicity text fields and birthplace were examined in detail to obtain accurate race/ethnicity group information for each decedent, thereby minimizing misclassification. Population denominators for the states of California and Texas were obtained from the 5-year American Community Survey (2008–2012) [15].

Cancer mortality rates for 2008–2012 were calculated per 100,000 persons, by sex, annualized and age-standardized to the 2000 US Standard Population using 18 age group bands, all 5-year except the last, 85 and older. Corresponding 95% confidence intervals (CIs) for mortality rates were calculated with gamma intervals modification. To directly compare rates between Latinos in aggregate, US-born Latinos, foreign-born Latinos and the referent NLW population, we computed age-adjusted site-specific mortality rate ratios using negative binomial regression. Models included decedents ages 40 and over.

SAS 9.3 was used for data analysis. This study was approved by the University of Nevada, Las Vegas Institutional Review Board. Data use agreements were obtained from each state.

Results

Cancer was the cause of death for 282,733 Californians and 183,018 Texans in 2008–2012. Among these, 44,283 (16%) in California and 33,073 (18%) in Texas were of Latino ethnicity. Of these Latino decedents, 43% in California and 33% in Texas were born outside of the 50 US states (Table 1).
Table 1

Characteristics of the Study Population by State, 2008–2012

 

Population Data (Census 2010 and American Community Survey)

Cancer Mortality Data (2008–2012)

 

Total Population

Deaths from Cancer

% Cancer/All Deaths

% Foreign-born within racial/ethnic group

CALIFORNIA

 Non-Latino White

14,956,253

185,789

24%

10%

 Non-Latino Black

2,436,082

21,024

23%

3%

 Latino

14,013,719

44,283

23%

57%

  US-Born

8,580,121

18,920

20%

0%

  Foreign-Born

5,433,598

25,363

25%

100%

 Mexican

12,055,090

35,832

22%

53%

 Central American

1,193,268

3845

25%

96%

 South American

309,569

1757

30%

96%

 Caribbeana

305,901

1652

21%

77%

 Other Latinob

149,891

1197

23%

15%

TEXAS

 Non-Latino White

11,397,345

122,899

22%

2%

 Non-Latino Black

3,019,318

22,690

23%

1%

 Latino

9,460,921

33,073

20%

33%

  US-Born

6,458,501

22,034

19%

0%

  Foreign-Born

3,002,420

11,039

25%

100%

a Includes Caribbean Latinos (Dominican Republic, Cuba and Puerto Rico)

b Includes those of Spaniard (European Spanish) origin or birthplace Spain

The leading causes of cancer mortality among Latinos overall were lung, prostate, female breast, colorectal (CRC), liver and pancreatic cancers, with only slight differences between the two states. Among all analyzed groups, foreign-born Latinos had the lowest all-cancers-combined mortality rates and NLBs had the highest. By cancer site, there was considerable heterogeneity: Latino mortality rates were lower than NLWs and NLBs for lung, breast and bladder cancers, among others; however, for stomach and cervical cancers, rates were similar to NLBs, and significantly higher than NLWs. For colorectal cancer, US-born Latino males in both states had high mortality rates, surpassed only by NLBs. In both states, liver and kidney mortality rates for US-born Latinos were the highest of all analyzed populations (Tables 2 and 3).
Table 2

Annual Age-Adjusteda Mortality Rates for Selected Cancers per 100,000, California, 2008–2012

 

All Combinedb

Non-Latino White

Non-Latino Black

All Latino

Foreign-born Latino

US-born Latino

 

N

Rate

95% CI

N

Rate

95% CI

N

Rate

95% CI

N

Rate

95% CI

N

Rate

95% CI

N

Rate

95% CI

Male

Oral Cavity and Pharynx

3128

3.7

(3.6–3.9)

2088

4.2

(4.0–4.4)

207

4.3

(3.7–4.9)

400

2.5

(2.2–2.7)

217

2.1

(1.8–2.4)

183

3.1

(2.6–3.6)

Esophagus

4935

6.1

(6.0–6.3)

3705

7.6

(7.4–7.9)

207

4.8

(4.1–5.5)

667

4.4

(4.0–4.7)

349

3.5

(3.1–3.9)

318

5.7

(5.1–6.4)

Stomach

4474

5.6

(5.5–5.8)

1876

3.9

(3.8–4.1)

369

8.8

(7.9–9.8)

1316

8.2

(7.7–8.7)

909

8.7

(8.1–9.4)

407

7.3

(6.6–8.1)

Colorectum

13,249

16.8

(16.5–17.1)

8114

17.0

(16.6–17.4)

1115

26.1

(24.5–27.7)

2380

15.5

(14.9–16.2)

1237

12.7

(12.0–13.6)

1143

20.0

(18.8–21.2)

Liver

9076

10.7

(10.4–10.9)

4028

8.0

(7.7–8.2)

685

13.3

(12.3–14.4)

2360

14.0

(13.4–14.6)

1078

10.7

(10.0–11.4)

1282

19.8

(18.6–20.9)

Gallbladder

353

0.4

(0.4–0.5)

169

0.3

(0.3–0.4)

17

0.4

(0.2–0.6)

102

0.7

(0.6–0.9)

57

0.6

(0.5–0.9)

45

0.8

(0.6–1.1)

Pancreas

9483

11.9

(11.7–12.2)

6126

12.6

(12.3–12.9)

696

15.7

(14.4–16.9)

1598

10.7

(10.1–11.2)

929

10.1

(9.4–10.9)

669

11.7

(10.8–12.7)

Lung

34,113

44.3

(43.8–44.8)

23,578

49.5

(48.8–50.1)

2718

63.5

(61.0–66.1)

3586

26.6

(25.7–27.5)

2079

25.2

(24.0–26.4)

1507

29.0

(27.5–30.6)

Melanoma

3148

3.9

(3.8–4.1)

2887

6.1

(5.9–6.3)

22

0.4

(0.3–0.7)

186

1.1

(1.0–1.3)

127

1.3

(1.1–1.6)

59

0.9

(0.7–1.2)

Prostate

15,326

21.4

(21.1–21.8)

10,406

22.3

(21.9–22.7)

1696

48.6

(46.3–51.1)

2212

19.2

(18.4–20.1)

1291

18.3

(17.3–19.4)

921

20.8

(19.4–22.2)

Kidney

4170

5.2

(5.0–5.3)

2639

5.4

(5.2–5.7)

264

5.7

(5.0–6.5)

890

5.6

(5.2–6.0)

453

4.5

(4.1–5.0)

437

7.2

(6.5–8.0)

Bladder

5037

6.9

(6.7–7.1)

4018

8.5

(8.3–8.8)

221

5.8

(5.0–6.6)

472

3.8

(3.5–4.2)

260

3.5

(3.1–4.0)

212

4.3

(3.7–5.0)

Brain

4507

5.3

(5.2–5.5)

3201

6.8

(6.6–7.1)

171

3.4

(2.9–4.0)

777

3.7

(3.4–4.0)

445

3.8

(3.4–4.2)

332

3.6

(3.1–4.1)

CUP

6686

8.5

(8.3–8.7)

4571

9.5

(9.2–9.8)

464

10.6

(9.6–11.7)

1019

6.7

(6.3–7.2)

585

6.2

(5.6–6.8)

434

7.5

(6.8–8.3)

NHL

5817

7.5

(7.3–7.7)

3861

8.2

(8.0–8.5)

265

5.9

(5.2–6.7)

1109

7.2

(6.7–7.7)

693

7.4

(6.8–8.1)

416

7.1

(6.4–7.8)

Leukemia

6685

8.6

(8.4–8.8)

4512

9.8

(9.5–10.1)

357

8.4

(7.5–9.4)

1179

6.2

(5.8–6.6)

598

5.9

(5.3–6.5)

581

6.7

(6.1–7.5)

All-sites-combined

145,045

185.9

(185.0–186.9)

95,579

200.7

(199.4–202.0)

10,567

250.4

(245.4–255.6)

22,838

152.0

(149.8–154.1)

12,691

138.9

(136.2–141.6)

10,147

174.1

(170.5–177.8)

Female

Oral Cavity and Pharynx

1452

1.4

(1.4–1.5)

960

1.6

(1.5–1.7)

100

1.7

(1.4–2.1)

179

0.9

(0.8–1.1)

104

0.9

(0.7–1.1)

75

1.0

(0.8–1.3)

Esophagus

1422

1.4

(1.3–1.5)

1038

1.7

(1.6–1.8)

105

1.8

(1.4–2.1)

138

0.7

(0.6–0.9)

70

0.6

(0.5–0.8)

68

0.9

(0.7–1.2)

Stomach

3282

3.3

(3.2–3.4)

1171

1.9

(1.8–2.0)

282

5.0

(4.4–5.6)

1077

5.2

(4.8–5.5)

746

5.6

(5.2–6.0)

331

4.4

(3.9–4.9)

Colorectum

12,559

12.2

(12.0–12.4)

8024

12.9

(12.6–13.2)

1112

19.4

(18.2–20.6)

1803

9.2

(8.8–9.7)

1034

8.5

(7.9–9.0)

769

10.5

(9.8–11.3)

Liver

4469

4.5

(4.3–4.6)

1907

3.2

(3.0–3.3)

323

5.4

(4.8–6.0)

1220

6.5

(6.1–6.9)

736

6.3

(5.9–6.8)

484

6.8

(6.2–7.5)

Gallbladder

785

0.8

(0.7–0.8)

333

0.5

(0.5–0.6)

44

0.8

(0.6–1.0)

294

1.6

(1.4–1.7)

221

1.9

(1.6–2.2)

73

1.0

(0.8–1.3)

Pancreas

9550

9.5

(9.3–9.7)

6029

9.9

(9.6–10.2)

753

13.3

(12.4–14.3)

1606

8.6

(8.2–9.1)

976

8.5

(8.0–9.1)

630

8.9

(8.2–9.7)

Lung

30,575

30.9

(30.5–31.2)

22,888

38.7

(38.2–39.3)

2223

38.7

(37.1–40.4)

2512

13.6

(13.1–14.2)

1334

11.8

(11.1–12.4)

1178

16.8

(15.9–17.9)

Melanoma

1599

1.6

(1.5–1.7)

1395

2.5

(2.3–2.6)

16

0.3

(0.2–0.4)

137

0.7

(0.6–0.8)

93

0.7

(0.6–0.9)

44

0.6

(0.4–0.8)

Breast

21,696

21.5

(21.2–21.8)

14,177

24.6

(24.1–25.0)

1960

32.7

(31.2–34.2)

3335

15.1

(14.6–15.7)

1977

13.9

(13.2–14.5)

1358

17.3

(16.3–18.2)

Cervix

2207

2.2

(2.2–2.3)

959

1.9

(1.8–2.1)

218

3.6

(3.1–4.1)

718

2.9

(2.7–3.1)

481

3.1

(2.8–3.4)

237

2.5

(2.2–2.9)

Endometrium

4444

4.4

(4.3–4.5)

2683

4.5

(4.3–4.7)

479

8.1

(7.4–8.9)

773

3.7

(3.4–4.0)

464

3.4

(3.1–3.8)

309

4.1

(3.7–4.6)

Ovary

7758

7.7

(7.6–7.9)

5186

8.9

(8.6–9.1)

447

7.6

(6.9–8.4)

1317

6.3

(6.0–6.7)

810

6.1

(5.7–6.6)

507

6.7

(6.1–7.4)

Kidney

2304

2.3

(2.2–2.4)

1406

2.3

(2.2–2.4)

133

2.3

(2.0–2.8)

528

2.7

(2.4–2.9)

281

2.3

(2.1–2.7)

247

3.3

(2.9–3.7)

Bladder

2071

2.0

(1.9–2.1)

1532

2.3

(2.2–2.5)

161

2.9

(2.5–3.4)

233

1.3

(1.1–1.5)

126

1.2

(1.0–1.4)

107

1.5

(1.2–1.8)

Brain

3489

3.5

(3.4–3.6)

2378

4.4

(4.2–4.6)

158

2.7

(2.3–3.1)

649

2.8

(2.6–3.0)

376

2.9

(2.6–3.2)

273

2.6

(2.2–2.9)

CUP

6229

6.1

(6.0–6.3)

4248

7.0

(6.8–7.2)

477

8.2

(7.5–9.0)

932

4.8

(4.5–5.1)

542

4.5

(4.1–5.0)

390

5.3

(4.7–5.8)

NHL

4715

4.6

(4.5–4.8)

3026

4.8

(4.6–5.0)

221

3.9

(3.4–4.5)

916

4.8

(4.5–5.2)

529

4.5

(4.1–5.0)

387

5.3

(4.8–5.9)

Leukemia

5158

5.1

(5.0–5.3)

3328

5.5

(5.4–5.8)

304

5.3

(4.7–6.0)

956

4.1

(3.9–4.4)

58

4.2

(3.8–4.6)

448

4.2

(3.8–4.7)

All-sites-combined

137,688

136.9

(136.2–137.7)

90,209

151.8

(150.8–152.8)

10,457

180.1

(176.6–183.6)

21,445

106.4

(104.9–107.9)

12,672

101.6

(99.8–103.5)

8773

114.7

(112.2–117.2)

Abbreviations: CUP cancers of unknown primary, NHL non-Hodgkin lymphoma; All-sites-combined includes all cancers, not only those listed here

a 2000 US Standard Population

b Includes all race/ethnicities

Table 3

Annual Age-Adjusteda Mortality Rates for Selected Cancers per 100,000, Texas, 2008–2012

 

All Combinedb

Non-Latino White

Non-Latino Black

All Latino

Foreign-born Latino

US-born Latino

 

N

Rate

95% CI

N

Rate

95% CI

N

Rate

95% CI

N

Rate

95% CI

N

Rate

95% CI

N

Rate

95% CI

Male

Oral Cavity and Pharynx

2108

4.0

(3.8–4.2)

1447

4.3

(4.1–4.5)

274

5.6

(4.9–6.4)

325

2.7

(2.4–3.0)

103

2.0

(1.6–2.5)

222

3.3

(2.9–3.8)

Esophagus

3134

6.1

(5.9–6.4)

2265

6.8

(6.5–7.1)

298

6.5

(5.7–7.4)

517

4.8

(4.4–5.3)

150

3.0

(2.5–3.6)

367

6.2

(5.6–6.9)

Stomach

2462

4.9

(4.7–5.1)

1052

3.3

(3.1–3.5)

403

9.4

(8.4–10.5)

878

7.8

(7.3–8.4)

304

6.1

(5.3–6.9)

574

9.3

(8.5–10.1)

Colorectum

9295

19.0

(18.6–19.4)

5698

18.1

(17.6–18.6)

1357

30.3

(28.5–32.1)

2009

18.4

(17.6–19.3)

556

11.6

(10.6–12.8)

1453

24.1

(22.8–25.5)

Liver

6153

11.4

(11.1–11.7)

2956

8.6

(8.3–9.0)

903

16.3

(15.2–17.5)

2004

17.1

(16.3–18.0)

503

10.5

(9.5–11.6)

1501

23.0

(21.7–24.2)

Gallbladder

240

0.5

(0.4–0.6)

118

0.4

(0.3–0.4)

29

0.8

(0.5–1.1)

79

0.8

(0.6–1.0)

29

0.6

(0.4–1.0)

50

0.9

(0.6–1.1)

Pancreas

5861

11.9

(11.6–12.2)

3902

12.1

(11.7–12.5)

670

15.2

(14.0–16.5)

1152

10.7

(10.1–11.4)

373

7.9

(7.0–8.8)

779

13.1

(12.1–14.1)

Lung

27,382

56.9

(56.2–57.6)

20,235

63.1

(62.2–64.0)

3492

81.9

(78.9–84.9)

3114

32.2

(31.0–33.4)

1044

25.2

(23.5–26.9)

2070

37.9

(36.2–39.6)

Melanoma

1824

3.7

(3.6–3.9)

1654

5.3

(5.0–5.5)

21

0.5

(0.3–0.8)

136

1.3

(1.0–1.5)

54

1.2

(0.9–1.6)

82

1.3

(1.0–1.7)

Prostate

8058

19.8

(19.3–20.2)

5280

18.7

(18.2–19.2)

1264

39.6

(37.3–42.0)

1405

17.6

(16.7–18.6)

557

16.3

(14.9–17.8)

848

18.6

(17.3–19.9)

Kidney

3286

6.6

(6.4–6.8)

2123

6.6

(6.3–6.9)

298

6.7

(5.8–7.5)

807

7.1

(6.6–7.6)

232

4.6

(4.0–5.4)

575

9.2

(8.4–10.0)

Bladder

2769

6.5

(6.2–6.7)

2251

7.7

(7.3–8.0)

190

5.3

(4.5–6.2)

279

3.1

(2.7–3.5)

91

2.2

(1.7–2.8)

188

3.8

(3.2–4.4)

Brain

2618

4.9

(4.7–5.1)

1921

6.0

(5.7–6.2)

162

3.0

(2.5–3.6)

476

3.4

(3.0–3.7)

178

2.9

(2.5–3.5)

298

3.7

(3.2–4.2)

CUP

5015

10.3

(10.0–10.6)

3421

10.8

(10.4–11.2)

558

12.4

(11.3–13.6)

917

8.3

(7.7–8.9)

289

6.5

(5.7–7.4)

628

9.9

(9.1–10.8)

NHL

3593

7.7

(7.5–8.0)

2489

8.2

(7.9–8.5)

264

5.7

(5.0–6.5)

768

7.1

(6.6–7.7)

249

5.3

(4.6–6.1)

519

8.6

(7.8–9.5)

Leukemia

4260

9.2

(8.9–9.5)

2950

9.9

(9.5–10.2)

384

8.9

(8.0–10.0)

832

6.9

(6.3–7.4)

248

5.4

(4.6–6.3)

584

8.3

(7.5–9.1)

All-sites-combined

97,730

203.3

(202.0–204.6)

66,085

210.1

(208.5–211.8)

11,736

274.7

(269.3–280.3)

17,668

166.4

(163.8–169.1)

5629

124.8

(121.2–128.5)

12,039

201.4

(197.6–205.3)

Female

Oral Cavity and Pharynx

837

1.3

(1.2–1.4)

607

1.5

(1.4–1.7)

97

1.5

(1.2–1.8)

108

0.8

(0.7–1.0)

31

0.5

(0.4–0.8)

77

1.0

(0.8–1.3)

Esophagus

726

1.2

(1.1–1.3)

518

1.3

(1.2–1.4)

88

1.4

(1.1–1.7)

109

0.9

(0.7–1.0)

36

0.7

(0.5–1.0)

73

1.0

(0.8–1.2)

Stomach

1728

2.8

(2.7–2.9)

679

1.7

(1.6–1.9)

262

4.3

(3.8–4.9)

700

4.9

(4.5–5.2)

262

3.9

(3.5–4.5)

438

5.6

(5.0–6.1)

Colorectum

7762

12.5

(12.2–12.8)

5025

12.6

(12.2–12.9)

1213

19.8

(18.6–20.9)

1342

9.9

(9.3–10.4)

379

6.3

(5.6–7.0)

963

12.6

(11.8–13.5)

Liver

2831

4.6

(4.5–4.8)

1374

3.5

(3.3–3.7)

322

5.0

(4.5–5.6)

996

7.8

(7.3–8.3)

347

6.2

(5.5–6.9)

649

9.0

(8.3–9.7)

Gallbladder

474

0.8

(0.7–0.8)

229

0.6

(0.5–0.7)

55

0.9

(0.7–1.2)

172

1.3

(1.1–1.5)

72

1.2

(0.9–1.6)

100

1.3

(1.1–1.6)

Pancreas

5505

9.0

(8.8–9.3)

3552

8.9

(8.6–9.2)

790

13.5

(12.6–14.5)

1031

8.0

(7.5–8.5)

359

6.5

(5.8–7.2)

672

9.2

(8.5–9.9)

Lung

20,606

33.9

(33.5–34.4)

16,047

41.0

(40.3–41.6)

2318

38.4

(36.8–40.0)

1806

14.0

(13.4–14.7)

677

12.2

(11.2–13.2)

1129

15.5

(14.6–16.5)

Melanoma

892

1.4

(1.3–1.5)

765

2.0

(1.9–2.2)

25

0.4

(0.3–0.6)

93

0.6

(0.5–0.8)

40

0.6

(0.4–0.8)

53

0.7

(0.5–0.9)

Breast

13,264

21.2

(20.8–21.5)

8205

21.1

(20.7–21.6)

2212

33.5

(32.1–35.0)

2518

16.5

(15.8–17.2)

931

13.4

(12.5–14.3)

1587

19.2

(18.3–20.2)

Cervix

1733

2.8

(2.6–2.9)

800

2.3

(2.2–2.5)

286

4.1

(3.7–4.7)

608

3.6

(3.3–3.9)

233

3.2

(2.8–3.7)

375

4.1

(3.7–4.5)

Endometrium

2307

3.7

(3.5–3.9)

1266

3.2

(3.0–3.4)

420

6.9

(6.2–7.6)

545

3.7

(3.4–4.0)

187

2.9

(2.5–3.4)

358

4.4

(4.0–4.9)

Ovary

4512

7.3

(7.1–7.5)

3092

7.9

(7.7–8.2)

425

7.0

(6.3–7.7)

880

6.1

(5.7–6.5)

304

4.7

(4.1–5.3)

576

7.2

(6.6–7.8)

Kidney

1834

3.0

(2.8–3.1)

1119

2.8

(2.6–3.0)

204

3.3

(2.9–3.8)

474

3.6

(3.2–3.9)

159

2.7

(2.3–3.2)

315

4.3

(3.8–4.8)

Bladder

1116

1.8

(1.7–2.0)

804

2.0

(1.8–2.1)

146

2.6

(2.2–3.0)

155

1.2

(1.0–1.4)

49

1.0

(0.7–1.3)

106

1.5

(1.2–1.8)

Brain

2096

3.3

(3.2–3.5)

1517

4.1

(3.9–4.3)

141

2.1

(1.8–2.5)

388

2.3

(2.1–2.6)

120

2.2

(1.6–2.9)

268

2.8

(2.5–3.2)

CUP

4169

6.8

(6.6–7.0)

2802

7.0

(6.8–7.3)

508

8.3

(7.6–9.1)

751

5.6

(5.2–6.0)

276

4.8

(4.2–5.4)

475

6.3

(5.7–6.9)

NHL

2831

4.7

(4.5–4.8)

1952

4.9

(4.7–5.1)

201

3.3

(2.8–3.8)

613

4.7

(4.3–5.1)

231

4.2

(3.6–4.8)

382

5.2

(4.6–5.7)

Leukemia

3218

5.3

(5.1–5.5)

2189

5.6

(5.4–5.9)

299

5.0

(4.4–5.6)

644

4.1

(3.7–4.4)

206

3.4

(2.9–4.0)

438

4.7

(4.2–5.2)

All-sites-combined

85,288

138.6

(137.6–139.5)

56,814

145.0

(143.8–146.2)

10,954

176.8

(173.4–180.2)

15,405

110.1

(108.3–111.9)

5410

89.0

(86.4–91.6)

9995

127.7

(125.1–130.3)

Abbreviations: CUP cancers of unknown primary, NHL non-Hodgkin lymphoma; All-sites-combined includes all cancers, not only those listed here

a 2000 US Standard Population

b Includes all race/ethnicities

Compared to NLWs, the risk of cancer death for Latinos in aggregate for all-cancers-combined was 23% and 26% lower in Texas and California, respectively, for both sexes combined (p < 0.05). However, in both states, significantly higher mortality was observed for stomach, cervix and gall bladder cancers for US-born and foreign-born Latinos compared to NLWs. Patterns for certain cancers, including liver, kidney and colorectal cancer, were markedly different between US-born and foreign-born Latinos, with significantly higher mortality seen in the US-born, consistent across both states. The largest difference was seen in liver cancer: US-born Latino men had 2.8 (95% CI: 2.5–3.2) and 2.7 (95% CI: 2.2–3.4) times higher liver cancer mortality than NLWs in California and Texas, respectively, while ratios for foreign-born Latino men were 1.2 (95%CI: 1.1–1.4) in California and 1.1 (95% CI: 0.9–1.3) in Texas (Table 4).
Table 4

Mortality Rate Ratiosa for Selected Cancers by Latino Ethnicity and Birthplace, CA and TX, 2008–2012

  

California

Texas

 

Non-Latino White

All Latino

US-born Latino

Foreign-born Latino

All Latino

US-born Latino

Foreign-born Latino

 

Referent

RR

95% CI

RR

95% CI

RR

95% CI

RR

95% CI

RR

95% CI

RR

95% CI

Male

Oral Cavity and Pharynx

1.00

0.57

(0.50–0.64)

0.74

(0.63–0.87)

0.46

(0.39–0.54)

0.62

(0.54–0.69)

0.79

(0.68–0.91)

0.42

(0.34–0.51)

Esophagus

1.00

0.56

(0.51–0.61)

0.74

(0.66–0.84)

0.45

(0.39–0.50)

0.65

(0.59–0.72)

0.86

(0.77–0.96)

0.41

(0.35–0.48)

Stomach

1.00

2.01

(1.86–2.18)

1.91

(1.66–2.18)

2.05

(1.82–2.30)

2.33

(2.13–2.55)

2.82

(2.55–3.13)

1.75

(1.54–1.99)

Colorectum

1.00

0.92

(0.88–0.97)

1.25

(1.17–1.34)

0.71

(0.66–0.76)

1.02

(0.96–1.07)

1.36

(1.28–1.45)

0.60

(0.55–0.66)

Liver

1.00

1.80

(1.69–1.92)

2.83

(2.52–3.18)

1.21

(1.07–1.37)

1.94

(1.68–2.25)

2.73

(2.22–3.36)

1.06

(0.85–1.32)

Gallbladder

1.00

2.14

(1.65–2.78)

2.59

(1.85–3.64)

1.83

(1.32–2.56)

2.07

(1.56–2.76)

2.40

(1.72–3.35)

1.67

(1.11–2.52)

Pancreas

1.00

0.83

(0.78–0.88)

0.99

(0.91–1.08)

0.73

(0.67–0.79)

0.87

(0.82–0.93)

1.09

(1.01–1.17)

0.62

(0.56–0.69)

Lung

1.00

0.48

(0.44–0.53)

0.57

(0.54–0.61)

0.44

(0.42–0.47)

0.46

(0.40–0.52)

0.56

(0.48–0.64)

0.34

(0.29–0.39)

Prostate

1.00

0.85

(0.81–0.89)

0.95

(0.88–1.02)

0.77

(0.73–0.83)

0.94

(0.88–1.00)

1.01

(0.92–1.09)

0.86

(0.78–0.95)

Kidney

1.00

1.06

(0.98–1.15)

1.44

(1.30–1.61)

0.82

(0.73–0.92)

1.09

(1.00–1.18)

1.45

(1.32–1.59)

0.67

(0.58–0.77)

Bladder

1.00

0.43

(0.38–0.47)

0.52

(0.44–0.60)

0.37

(0.32–0.42)

0.41

(0.36–0.46)

0.49

(0.42–0.57)

0.31

(0.25–0.38)

Brain

1.00

0.51

(0.46–0.56)

0.55

(0.48–0.64)

0.49

(0.43–0.55)

0.56

(0.50–0.62)

0.61

(0.53–0.70)

0.49

(0.42–0.58)

CUP

1.00

0.69

(0.64–0.75)

0.82

(0.74–0.92)

0.61

(0.55–0.67)

0.76

(0.71–0.82)

0.96

(0.88–1.05)

0.53

(0.47–0.60)

NHL

1.00

0.89

(0.82–0.96)

0.94

(0.84–1.04)

0.86

(0.78–0.94)

0.90

(0.83–0.98)

1.15

(1.00–1.31)

0.65

(0.56–0.76)

Leukemia

1.00

0.60

(0.56–0.66)

0.71

(0.63–0.81)

0.56

(0.49–0.63)

0.71

(0.65–0.79)

0.90

(0.79–1.02)

0.51

(0.44–0.60)

All-sites-combined

1.00

0.75

(0.58–0.96)

0.92

(0.90–0.94)

0.64

(0.63–0.65)

0.78

(0.76–0.80)

1.01

(0.93–1.09)

0.55

(0.51–0.60)

Female

Oral Cavity and Pharynx

1.00

0.55

(0.46–0.67)

0.72

(0.56–0.91)

0.44

(0.34–0.57)

0.49

(0.40–0.61)

0.65

(0.51–0.83)

0.30

(0.20–0.43)

Esophagus

1.00

0.42

(0.34–0.51)

0.61

(0.47–0.79)

0.28

(0.20–0.38)

0.64

(0.52–0.78)

0.76

(0.59–0.97)

0.47

(0.33–0.66)

Stomach

1.00

2.52

(2.29–2.77)

2.37

(2.05–2.75)

2.65

(2.28–3.08)

2.86

(2.56–3.18)

3.24

(2.87–3.66)

2.37

(2.05–2.74)

Colorectum

1.00

0.70

(0.66–0.74)

0.85

(0.79–0.92)

0.58

(0.54–0.63)

0.77

(0.73–0.82)

1.00

(0.93–1.07)

0.49

(0.44–0.55)

Liver

1.00

2.04

(1.86–2.23)

2.25

(1.95–2.60)

1.81

(1.57–2.08)

1.98

(1.68–2.34)

2.36

(2.00–2.79)

1.51

(1.28–1.81)

Gallbladder

1.00

2.76

(2.33–3.28)

2.05

(1.58–2.66)

3.28

(2.70–3.98)

2.16

(1.77–2.64)

2.30

(1.82–2.91)

2.00

(1.52–2.60)

Pancreas

1.00

0.87

(0.82–0.92)

0.94

(0.86–1.02)

0.82

(0.76–0.89)

0.88

(0.82–0.94)

1.03

(0.94–1.11)

0.69

(0.62–0.77)

Lung

1.00

0.35

(0.32–0.39)

0.45

(0.40–0.50)

0.29

(0.26–0.33)

0.32

(0.28–0.37)

0.35

(0.31–0.41)

0.27

(0.23–0.32)

Breast

1.00

0.63

(0.60–0.66)

0.73

(0.68–0.78)

0.55

(0.52–0.59)

0.79

(0.75–0.83)

0.92

(0.87–0.98)

0.64

(0.59–0.68)

Cervix

1.00

1.51

(1.34–1.69)

1.45

(1.23–1.71)

1.61

(1.41–1.83)

1.57

(1.38–1.79)

1.81

(1.46–2.24)

1.41

(1.11–1.78)

Endometrium

1.00

0.88

(0.81–0.96)

1.00

(0.89–1.13)

0.79

(0.71–0.89)

1.20

(1.03–1.39)

1.44

(1.22–1.70)

0.90

(0.74–1.09)

Ovary

1.00

0.71

(0.67–0.76)

0.81

(0.73–0.89)

0.65

(0.59–0.71)

0.78

(0.72–0.84)

0.93

(0.85–1.02)

0.59

(0.53–0.67)

Kidney

1.00

1.29

(1.16–1.44)

1.60

(1.39–1.84)

1.07

(0.92–1.23)

1.27

(1.14–1.41)

1.52

(1.34–1.72)

0.95

(0.80–1.12)

Bladder

1.00

0.54

(0.46–0.64)

0.67

(0.54–0.82)

0.45

(0.36–0.56)

0.63

(0.53–0.74)

0.76

(0.62–0.93)

0.45

(0.34–0.61)

Brain

1.00

0.57

(0.51–0.63)

0.60

(0.51–0.71)

0.55

(0.48–0.63)

0.57

(0.50–0.64)

0.78

(0.63–0.91)

0.42

(0.32–0.55)

CUP

1.00

0.71

(0.66–0.77)

0.80

(0.72–0.90)

0.64

(0.58–0.72)

0.78

(0.72–0.85)

0.89

(0.81–0.93)

0.64

(0.56–0.72)

NHL

1.00

1.00

(0.92–1.09)

1.14

(1.02–1.28)

0.90

(0.80–1.00)

0.96

(0.87–1.05)

1.05

(0.94–1.17)

0.83

(0.73–0.96)

Leukemia

1.00

0.72

(0.65–0.81)

0.74

(0.64–0.86)

0.64

(0.56–0.73)

0.73

(0.64–0.83)

0.87

(0.74–1.03)

0.58

(0.48–0.70)

All-sites-combined

1.00

0.73

(0.58–0.92)

0.80

(0.78–0.82)

0.64

(0.63–0.66)

0.76

(0.74–0.77)

0.89

(0.86–0.91)

0.60

(0.58–0.62)

Abbreviations: CUP cancers of unknown primary, NHL non-Hodgkin lymphoma; All-sites-combined includes all cancers, not only those listed here

a Negative binomial regression rate ratios adjusted for age groups 40+ years

Discussion

This is the first detailed analysis of cancer mortality by site for Latinos disaggregated by birthplace, US-born vs foreign-born. While mortality rates for all Latinos combined were lower than for NLWs as expected, the profile changed substantially when birthplace was considered. Among US-born Latinos, males in Texas had similar overall mortality rates to NLWs (RR = 1.01; 95% CI 0.93–1.09), while Texas females were 11% lower; similarly, in California, mortality rates were 8% and 20% lower for males and females, respectively. This unprecedented proximity of overall rates between NLWs and US-born Latino populations runs counter to the prevailing narrative of Latinos having significantly better cancer outcomes [1, 16].

Theories of the negative effects of acculturation [8] might lead one to think that US-born Latino cancer mortality outcomes are simply converging with the majority NLW population. However, this is not uniformly the case; substantial heterogeneity was seen by cancer site. Non-Latino whites were more vulnerable to lung, breast, bladder and melanoma mortality, while US-born Latino mortality was excessive for liver, kidney and CRC (in males), as well as for stomach, cervix and gall bladder, previously documented [1]. Some of these results align with existing knowledge of racial/ethnic patterns in risk factors: for lung, breast, cervical, and stomach cancers, differences in prevalence of risk factors such as smoking, reproductive patterns, human papillomavirus (HPV) and Helicobacter pylori infection are explanatory [16, 17].

Additional results from this study are surprising, such as the similar or slightly higher rates for some cancers for US-born Latinos compared to NLWs. These include pancreas, endometrium, prostate cancer, and non-Hodgkin lymphoma (NHL), not previously shown to be this high in a predominantly Mexican Latino population. While not the sole risk factor, obesity is associated with increased risk of liver, kidney, CRC, pancreas and endometrial cancers [18]. Thus, the high prevalence of obesity documented among US-born Latinos [19, 20] suggests this should be a target for intervention.

Unique patterns deserving of further discussion include liver, kidney and CRC.

Liver

The exceedingly high liver cancer mortality found in Latinos, especially among the US-born, whose rates are more than double those of NLWs, constitutes a true disparity. Unlike for NLWs, liver cancer was consistently one of the top four main causes of cancer death for both US-born and foreign-born male and female Latino populations. Our results confirm those from a previous mortality study using data through 2002 [21], as well as more recent incidence studies [22, 23].

Historically, liver cancer has been more common in developing countries and among US Latino and Asian immigrant populations, a pattern driven by their higher prevalence of hepatitis B infection (HBV) [24, 25]. With the implementation of HBV vaccination programs globally, this determinant of liver cancer, while still relevant, has reduced in prominence in the US [24, 26]. Instead, chronic infection with the hepatitis C virus (HCV) has been linked to the recent liver cancer incidence increases seen in the US, especially among the birth cohort of 1945–1965 [24, 26]. HCV infection in the US most often results from intravenous drug use and/or past transfusions with contaminated blood [26]. With the shifting roles of these two viral hepatitis infections, relative patterns for liver cancer between racial/ethnic groups in the US have also changed.

In our study, we found distinct patterns by gender. Foreign-born Latino men had liver cancer mortality rates similar to (California) or only slightly higher than (Texas) the referent NLW population. However, foreign-born Latina women in both states had significantly higher rates than NLW women, findings that are consistent with a recent study of diverse foreign-born Latinos in Florida [4]. Among US-born Latinos, liver cancer mortality rates were also higher for females compared to their NLW counterparts; however, they were exceedingly high for males, almost three times higher than NLWs in both states. While Latinos, especially the US-born, have high prevalence of some important risk factors for liver cancer [27], including obesity [9], diabetes [20], and heavy alcohol consumption among men [28], differences in HCV prevalence by gender and birthplace more likely explain the unique mortality patterns observed in this study.

Previous studies have attributed approximately 20% of US liver cancer cases to infection with HCV [27, 29]. However, these estimates are highly dependent upon methodology, especially the inclusion of relevant confounders. Bypassing these problems by using direct linkage between cancer registry data and viral hepatitis data, a recent study in New York City (NYC) found that a remarkable 40% of all NLW, 48% of all Latino, and 51% of all NLB new liver cancer cases in NYC were HCV-positive [30]. These results suggest that the role of HCV infection in the liver cancer “epidemic” may have been thus far underestimated. Additionally, regarding birthplace and HCV, researchers using NHANES data showed that US-born Latino males, with an elevated age-adjusted prevalence of HCV of 5.4%, have an approximately 8-times higher prevalence of HCV infection than their foreign-born Latino male counterparts [31]. Yet, among females, the prevalence ratio of HCV between US-born and foreign-born is comparatively lower, only 4-fold [31]. Furthermore, the overall prevalence of HCV among foreign-born Latinos was found to be lower than NLWs of both sexes [32]. Collectively, these data point towards the role of HCV prevalence in potentially explaining the differences in liver cancer mortality not only between US-born and foreign-born Latinos, but also between Latino males and females in relation to their NLW counterparts. Further research is needed to assess these gender-specific differences, especially given the likelihood that causal factors other than HCV play a larger role in liver cancer among the foreign-born, particularly among women. Moreover, this liver cancer disparity among US-born Latinos warrants specific interventions, possibly including targeted HCV screening and treatment as well as other public health measures aimed at reducing non-viral liver cancer risk factors in the Latino community, including obesity and metabolic disorders.

Kidney

Mortality rates for kidney cancer were 44% higher in US-born Latino males than NLWs, and 52% (TX) and 60% (CA) higher in US-born females; foreign-born Latinos had lower (men) or similar (women) mortality from kidney cancer compared to NLWs. Obesity likely explains much of this disparity: the population-attributable fraction of overweight/obesity as a risk factor for kidney cancer has been estimated at over 40% [18]. US-born Latinos, especially US-born Mexicans, have a much higher prevalence of obesity than NLWs; historically foreign-born Latinos have had relatively lower prevalence of obesity, especially men [19, 20, 33]. Two additional known risk factors for kidney cancer are smoking and hypertension, the latter independent of obesity [34]. Yet, Latinos, even the US-born, smoke less than NLWs [20]. Notably, while hypertension prevalence is similar between Latinos and NLWs, treatment and control of hypertension is much lower in Latinos [20].

The high kidney cancer mortality rates found here in US-born Latinos approach national rates recorded among American Indians [35], previously documented with the highest kidney cancer burden in the US, for whom prevalence of obesity, smoking, and hypertension are universally high [16, 36]. These risk factors are common correlates of lower socio-economic status, a shared feature between American Indian and US-born Latinos. Both minority populations are disadvantaged in education level and poverty, as well as access to quality healthcare [20, 35]. The unique vulnerability of US-born Latino and American Indian populations to kidney cancer requires additional investigation and public health attention to fully understand and eliminate this disparity.

Colorectal

In both states, US-born Latino men showed approximately 30% higher colorectal cancer mortality than NLW men, while mortality for US-born Latino women was only slightly lower (CA) or equivalent (TX) to their NLW counterparts. These findings contrast with previously recorded national rate ratios between Latinos in aggregate and NLWs during the same time period, 0.9 for men and 0.7 for women [1], demonstrating the importance of examining Latino cancer outcomes by birthplace. CRC risk factors that are high among US-born Latinos include obesity [9], diabetes [20], and heavy alcohol consumption among men [28], as previously mentioned. Additionally, low CRC screening among Latinos, especially men [20, 37], may further explain the disparity observed here. While other populations have seen declines in CRC mortality, attributed to increases in CRC screening [1], one recent study in California showed that low screening was driving a stable CRC mortality trend for Latinos [38]. Our findings suggest the same is happening in Texas; thus, this may be a problem with a national dimension. Given the high CRC mortality for US-born Latinos, continued efforts to increase the uptake of CRC screening and expand health care access are warranted in Latino communities.

This study presents valuable new data that provides evidence of cancer mortality disparities in the Latino population in the United States. Specific Latino ethnic group has been shown to be a major determinant of cancer mortality differences, as seen in Florida for Cubans, Puerto Ricans, Mexicans, Central and South Americans, and Dominicans [4]. However, independent of ethnic group, birthplace is a major determinant and confounder of cancer mortality rates, as shown here. Therefore, to generalize Latino cancer outcomes in the US without considering both ethnic group and birthplace is counterproductive. Across the US, regional variation in birthplace is remarkable, and confounds aggregate Latino rates by state and especially nationally. For example, in Florida an overwhelming 92% of Latino cancer decedents between 2008 and 2012 were foreign-born [4], while in this study only 43% were foreign-born in California and 33% in Texas. As an additional strength, our study benefits from very high completeness (>99%) of birthplace information for all decedents, which, combined with ethnicity and text descriptors, allowed for unprecedented reliable classification of Latinos by birthplace.

While it is possible that terminally ill Latinos could have returned to their home countries of origin to die, this out-migration has been found to be very small among Latinos [39, 40], and furthermore, would not affect the rates for US-born Latinos. Because we have previously shown Latino origin/ethnic group to be a major confounder in Latino cancer studies at large [4], we calculated disaggregated rates for Mexicans, Central Americans, and Other Latinos for the state of California, presented in Table 5. However, in California, 81% of all Latino decedents in our study were of Mexican origin, while Texas was even higher at 91%. Therefore, for these two states, not including origin/ethnic group data is unlikely to have biased our analysis.
Table 5

Annual Age-Adjusteda Mortality Rates for Latino Ethnic Groups per 100,000, California, 2008–2012

 

All Latinoa

Mexican

Central American

South American

Caribbean

 

N

Rate

95% CI

N

Rate

95% CI

N

Rate

95% CI

N

Rate

95% CI

N

Rate

95% CI

MALE

Oral Cavity and Pharynx

400

2.5

(2.2–2.7)

332

2.5

(2.2–2.8)

23

2.0

(1.1–3.1)

<10

1.5

(0.6–3.0)

22

3.7

(2.3–5.6)

Esophagus

667

4.4

(4.0–4.7)

558

4.4

(4.0–4.8)

40

4.0

(2.7–5.6)

14

2.6

(1.3–4.4)

31

5.4

(3.6–7.7)

Stomach

1316

8.2

(7.7–8.7)

1051

8.1

(7.6–8.6)

166

11.6

(9.5–14.0)

53

9.1

(6.7–12.0)

30

5.2

(3.5–7.5)

Colorectum

2380

15.5

(14.9–16.2)

1996

15.6

(14.9–16.4)

125

9.1

(7.3–11.3)

82

15.4

(12.1–19.4)

107

19.8

(16.1–23.9)

Liver

2360

14.0

(13.4–4.6)

2034

14.6

(13.9–15.3)

154

11.9

(9.8–14.4)

53

9.4

(6.9–12.5)

72

12.1

(9.4–15.3)

Gallbladder

102

0.7

(0.6–0.9)

86

0.7

(0.6–0.9)

<10

0.5

(0.2–1.2)

<10

1.1

(0.3–2.6)

<10

0.2

(0.0–1.0)

Pancreas

1598

10.7

(10.1–11.2)

1315

10.6

(10.0–11.2)

116

10.0

(8.0–12.4)

70

13.5

(10.3–17.2)

56

10.1

(7.5–13.1)

Lung

3586

26.6

(25.7–27.5)

2925

26.5

(25.4–27.5)

171

17.1

(14.3–20.2)

162

29.3

(24.7–34.4)

206

37.9

(32.8–43.5)

Melanoma

186

1.1

(1.0–1.3)

141

1.0

(0.9–1.2)

12

0.9

(0.4–1.7)

13

2.1

(1.1–3.7)

<10

1.4

(0.6–2.7)

Prostate

2212

19.2

(18.4–20.1)

1795

18.9

(18.1–19.9)

132

16.8

(13.8–20.2)

107

22.9

(18.6–27.9)

109

22.3

(18.3–26.9)

Kidney

890

5.6

(5.2–6.0)

754

5.7

(5.3–6.2)

44

2.7

(1.8–3.8)

30

5.1

(3.3–7.6)

38

4.5

(2.8–6.7)

Bladder

472

3.8

(3.5–4.2)

377

3.6

(3.2–4.0)

23

3.3

(2.0–4.9)

26

5.7

(3.7–8.2)

22

7.0

(4.9–9.6)

Brain

777

3.7

(3.4–4.0)

619

3.6

(3.3–3.9)

84

4.2

(3.2–5.6)

32

4.9

(3.3–7.1)

23

3.8

(2.4–5.8)

CUP

1019

6.7

(6.3–7.2)

838

6.6

(6.2–7.1)

69

5.5

(4.0–7.2)

44

8.3

(5.9–11.2)

39

6.8

(4.8–9.4)

NHL

1109

7.2

(6.7–7.7)

916

7.2

(6.7–7.7)

93

7.6

(5.9–9.7)

39

6.9

(4.8–9.6)

41

7.2

(5.1–9.8)

Leukemia

1179

6.2

(5.8–6.6)

970

6.0

(5.5–6.4)

105

6.6

(5.1–8.3)

42

7.3

(5.1–10.0)

32

5.8

(3.9–8.2)

All-sites-combined

22,838

152.0

(149.8–154.1)

18,863

151.6

(149.2–153.9)

1550

127.2

(119.6–135.1)

871

161.2

(150.1–173.0)

927

169.5

(158.6–181.0)

FEMALE

Oral Cavity and Pharynx

179

0.9

(0.8–1.1)

136

0.9

(0.7–1.1)

23

1.2

(0.7–1.8)

<10

1.1

(0.5–2.1)

<10

0.9

(0.4–2.0)

Esophagus

138

0.7

(0.6–0.9)

104

0.7

(0.6–0.8)

17

0.9

(0.5–1.4)

<10

0.8

(0.3–1.7)

<10

0.7

(0.2–1.7)

Stomach

1077

5.2

(4.8–5.5)

805

4.9

(4.5–5.2)

193

8.2

(7.1–9.6)

47

5.7

(4.2–7.6)

10

1.4

(0.6–2.5)

Colorectum

1803

9.2

(8.8–9.7)

1376

8.9

(8.4–9.4)

188

8.8

(7.6–10.2)

89

10.9

(8.7–13.5)

89

12.2

(9.8–15.0)

Liver

1220

6.5

(6.1–6.9)

987

6.7

(6.3–7.2)

150

7.4

(6.2–8.7)

36

4.4

(3.1–6.2)

34

4.7

(3.3–6.6)

Gallbladder

294

1.6

(1.4–1.7)

227

1.5

(1.3–1.7)

44

2.3

(1.7–3.1)

12

1.5

(0.8–2.7)

<10

1.0

(0.4–2.1)

Pancreas

1606

8.6

(8.2–9.1)

1267

8.7

(8.2–9.2)

151

7.5

(6.3–8.8)

75

9.2

(7.2–11.6)

58

8.1

(6.1–10.5)

Lung

2512

13.6

(13.1–14.2)

1993

13.8

(13.2–14.4)

207

10.4

(8.9–11.9)

112

13.6

(11.2–16.4)

115

16.3

(13.4–19.5)

Melanoma

137

0.7

(0.6–0.8)

110

0.7

(0.5–0.8)

<10

0.3

(0.1–0.6)

<10

0.7

(0.2–1.5)

<10

0.7

(0.2–1.6)

Breast

3335

15.1

(14.6–15.7)

2672

15.1

(14.5–15.7)

317

12.7

(11.3–14.3)

133

15.2

(12.7–18.1)

129

18.1

(15.1–21.5)

Cervix

718

2.9

(2.7–3.1)

584

2.9

(2.7–3.2)

101

4.0

(3.2–5.0)

16

1.8

(1.0–2.9)

11

1.6

(0.7–2.8)

Endometrium

773

3.7

(3.4–4.0)

632

3.8

(3.5–4.1)

81

3.5

(2.8–4.4)

24

2.7

(1.7–4.1)

18

2.5

(1.5–3.9)

Ovary

1317

6.3

(6.0–6.7)

1033

6.3

(5.9–6.7)

172

7.3

(6.2–8.5)

47

5.3

(3.9–7.1)

36

5.0

(3.5–6.9)

Kidney

528

2.7

(2.4–2.9)

452

2.9

(2.6–3.2)

40

1.8

(1.2–2.4)

17

1.1

(0.5–2.1)

<10

1.2

(0.5–2.3)

Bladder

233

1.3

(1.1–1.5)

179

1.3

(1.1–1.5)

22

1.3

(0.8–1.9)

<10

2.1

(1.2–3.3)

<10

1.2

(0.5–2.3)

Brain

649

2.8

(2.6–3.0)

497

2.6

(2.4–2.9)

84

3.7

(2.9–4.6)

32

3.8

(2.6–5.4)

18

2.5

(1.5–4.0)

CUP

932

4.8

(4.5–5.1)

757

5.0

(4.6–5.4)

77

3.5

(2.7–4.4)

44

5.4

(3.9–7.2)

34

4.7

(3.2–6.5)

NHL

916

4.8

(4.5–5.2)

713

4.8

(4.4–5.1)

101

4.9

(4.0–6.1)

39

4.7

(3.3–6.4)

29

4.0

(2.7–5.8)

Leukemia

956

4.1

(3.9–4.4)

768

4.0

(3.7–4.3)

105

4.5

(3.6–5.5)

29

3.6

(2.4–5.3)

36

4.9

(3.4–6.8)

All-sites-combined

21,445

106.4

(104.9–107.9)

16,969

106.0

(104.4–107.7)

2295

104.0

(99.5–108.5)

886

106.8

(99.8–114.1)

725

101.6

(94.3–109.3)

Central American (major group, Salvadorans, 48%); South American (major group, Peruvians, 28%); Caribbean includes Puerto Ricans, Cubans, Dominicans

Abbreviations: CUP cancers of unknown primary, NHL non-Hodgkin lymphoma; All-sites-combined includes all cancers, not only those listed here

a 2000 US Standard Population

b Includes those of Spaniard (European Spanish) origin or birthplace Spain

Mortality is primarily a function of cancer incidence; however, it is possible that limited quality health care access for Latinos results in poor cancer survival, thus impacting the mortality burden. While analyzing any differential survival between US-born and foreign-born Latinos can be problematic [41, 42], the Surveillance, Epidemiology and End Results (SEER) program, which conducts follow-up for more than 95% of all cancer patients, shows almost no differences in overall survival between NLWs and its Latino population, overwhelmingly Mexican [43]. Therefore, the mortality differences seen in our study are likely driven by differences in cancer incidence, rather than survival. Notwithstanding, future accurate survival studies with complete follow-up, especially in Texas, a non-SEER state, are warranted to assess the contribution of differential survival to these mortality patterns.

Conclusions

There are two main conclusions to be drawn from this study. First, in order for cancer indicators for Latinos to be accurate and useful in cancer prevention and control efforts, both ethnic group and birthplace must be taken into consideration. The Latino “advantage” in mortality does apply to foreign-born Latinos, but less so to US-born Latinos, suggesting that in aggregate, foreign-born status is the advantage, rather than ethnicity per se. Moreover, as previously suggested, the cancer advantage for Latinos seems, at least for men, to be largely an effect of tobacco smoking trends [19, 44]. If the excess in mortality from lung cancer (and melanoma whose rate is inherently higher) among NLWs were subtracted, overall mortality rates among US-born Latino men would be higher than NLWs in Texas, and similar in California.

Secondly, but more importantly, this elevated cancer mortality among US-born Latinos is an important and worrisome indicator. Since 2000, the share of foreign-born among Latinos has been declining, and birth has replaced migration as the primary source of population growth [14]. The role of negative acculturation among Latinos should be further studied given that the prevalence of many factors implicated in increased cancer mortality - HCV, obesity, diabetes, and uncontrolled hypertension – are now higher among US-born Latinos than NLWs, the host population to which Latinos supposedly acculturate. Already, current data from the California Health Information Survey shows only minimal differences between US-born and foreign born Latinos for smoking, obesity, and diabetes [45]. Thus, the offsetting of cancer rates by the “healthier” foreign-born among Latinos will not be a long-lasting trend. As US-born Latino rates for some cancers begin to approximate American Indian and African American populations, long known to be disadvantaged, the narrative describing Latino cancer outcomes will need to align with critical examination of the role of social determinants of health among US minority populations.

Abbreviations

CA: 

California

CI: 

Confidence intervals

CRC: 

Colorectal cancer

CUP: 

Cancers of unknown primary

HBV: 

Hepatitis B virus

HCV: 

Hepatitis C virus

HPV: 

Human papillomavirus

NHL: 

Non-Hodgkin lymphoma

NLB: 

Non-Latino black

NLW: 

Non-Latino white

NYC: 

New York City

SEER: 

Surveillance, Epidemiology and End Results

TX: 

Texas

US: 

United States

Declarations

Acknowledgements

The authors would like to thank Fabienne Laraque, MD, MPH, Director, Viral Hepatitis Program, BCD, NYC, DOHMH for her assistance.

Funding

Paulo S. Pinheiro is partially funded by the National Institute of General Medical Sciences (8 P20 GM103440–11). NIGMS sponsors his research on disparities in cancer but has no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

Restrictions from California and Texas Departments of Health apply to the availability of these data. The authors themselves are unauthorized to share the individual-level data.

Authors’ contributions

PSP: project conceptualization, data curation and formal analyses, data presentation/visualization, interpretation of data, drafting of original manuscript, revising and editing final manuscript, approval of final version of the manuscript. KEC: data curation and formal analyses, data presentation/visualization, interpretation of data, drafting of original manuscript, revising and editing final manuscript, approval of final version of the manuscript. SLG: interpretation of data, revising and editing final manuscript, approval of final version of the manuscript. RM-G: interpretation of data, revising and editing final manuscript, approval of final version of the manuscript. TRC: interpretation of data, data presentation/visualization, revising and editing final manuscript, approval of version of the manuscript. AR-B: interpretation of data, revising and editing final manuscript, approval of final version of the manuscript. AGR: interpretation of data, revising and editing final manuscript, approval of final version of the manuscript.

Ethics approval and consent to participate

This study was approved by the University of Nevada, Las Vegas Institutional Review Board; excluded as “Not Human Subjects Research” under Protocol # 798947-1. Data use agreements were obtained from California and Texas. The mortality data that support the findings of this study were obtained by special permission from the State of California, Department of Public Health, Center for Health Statistics and Informatics, Health Information and Research Section and the State of Texas, Texas Department of State Health Services, Center for Health Statistics.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
School of Community Health Sciences, University of Nevada Las Vegas
(2)
Cancer Prevention Institute of California
(3)
Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Biomedical Research Institute (IdiBGi)
(4)
Department of Epidemiology and Biostatics, Institute for Health Promotion Research, University of Texas Health Science Center at San Antonio

References

  1. Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, Martinez-Tyson D, et al. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin. 2015;65(6):457–80.View ArticlePubMedGoogle Scholar
  2. U.S. Census Bureau, Census 2010: Summary File 1, Detailed Tables, Tables QT-PCT-10; Summary File 2, Detailed Tables, PCT-3. Available at https://factfinder.census.gov/faces/tableservices/jsf/pages/productview.xhtml?src=bkmk. Accessed 1 Oct 2016.
  3. Pinheiro PS, Sherman RL, Trapido EJ, Fleming LE, Huang Y, Gomez-Marin O, et al. Cancer incidence in first generation U.S. Hispanics: Cubans, Mexicans, Puerto Ricans, and new Latinos. Cancer Epidemiol Biomark Prev. 2009;18(8):2162–9.View ArticleGoogle Scholar
  4. Pinheiro PS, Callahan KE, Siegel RL, Jin H, Morris CR, Trapido EJ, et al. Cancer mortality in Hispanic ethnic groups. Cancer Epidemiol Biomark Prev. 2017;26(3):376–82.View ArticleGoogle Scholar
  5. Kennedy S, Kidd MP, McDonald JT, Biddle N. The healthy immigrant effect: patterns and evidence from four countries. J Int Migr Integr. 2015;16(2):317–32.View ArticleGoogle Scholar
  6. Singh GK, Rodriguez-Lainz A, Kogan MD. Immigrant health inequalities in the United States: use of eight major national data systems. ScientificWorldJournal. 2013;2013:512313.PubMedPubMed CentralGoogle Scholar
  7. Schwartz SJ, Unger JB, Zamboanga BL, Szapocznik J. Rethinking the concept of acculturation: implications for theory and research. Am Psychol. 2010;65(4):237.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Abraido-Lanza AF, Chao MT, Florez KR. Do healthy behaviors decline with greater acculturation?: implications for the Latino mortality paradox. Soc Sci Med. 2005;61(6):1243–55.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Lara M, Gamboa C, Kahramanian MI, Morales LS, Hayes Bautista DE. Acculturation and Latino health in the United States: a review of the literature and its sociopolitical context. Annu Rev Public Health. 2005;26:367–97.View ArticlePubMedGoogle Scholar
  10. Singh GK, Hiatt RA. Trends and disparities in socioeconomic and behavioural characteristics, life expectancy, and cause-specific mortality of native-born and foreign-born populations in the United States, 1979–2003. Int J Epidemiol. 2006;35(4):903–19.View ArticlePubMedGoogle Scholar
  11. Tao L, Ladabaum U, Gomez SL, Cheng I. Colorectal cancer mortality among Hispanics in California: differences by neighborhood socioeconomic status and birthplace. Cancer. 2014;120(22):3510–8.View ArticlePubMedGoogle Scholar
  12. Eschbach K, Stimpson JP, Kuo Y, Goodwin JS. Mortality of foreign-born and US-born Hispanic adults at younger ages: a reexamination of recent patterns. Am J Public Health. 2007;97(7):1297–304.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Pinheiro PS, Callahan K, Ragin C, Hage R, Hylton T, Kobetz E. Black heterogeneity in cancer mortality: US-blacks, Haitians, and Jamaicans. Cancer Control. 2016;23(4):347–58.PubMedGoogle Scholar
  14. Stepler R, Brown A. Statistical Portrait of Hispanics in the United States. Pew Hispanic Center; April 19, 2016. Available at http://www.pewhispanic.org/2016/04/19/statistical-portrait-of-hispanics-in-the-unitedstates/.
  15. Ruggles S, Genadek KE, Goeken R, Grover J, and Sobek M. Integrated public use microdata series: version 6.0 [machine-readable database]. American community survey 2012 5-year estimates. Minneapolis: University of Minnesota. Accessed Sept 2016.Google Scholar
  16. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.View ArticlePubMedGoogle Scholar
  17. Howe HL, Wu X, Ries LA, Cokkinides V, Ahmed F, Jemal A, et al. Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among US Hispanic/Latino populations. Cancer. 2006;107(8):1711–42.View ArticlePubMedGoogle Scholar
  18. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–91.View ArticlePubMedGoogle Scholar
  19. Goldman N. Will the Latino mortality advantage endure? Res Aging. 2016;38(3):263–82.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Dominguez K, Penman-Aguilar A, Chang M, Moonesinghe R, Castellanos T, Rodriguez-Lainz A, et al. Vital signs: leading causes of death, prevalence of diseases and risk factors, and use of health services among Hispanics in the United States—2009–2013. MMWR Morb Mortal Wkly Rep. 2015;64(17):469–78.PubMedGoogle Scholar
  21. HB E-S, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76.View ArticleGoogle Scholar
  22. Setiawan VW, Wei PC, Hernandez BY, Lu SC, Monroe KR, Le Marchand L, et al. Disparity in liver cancer incidence and chronic disease mortality by birthplace in Hispanic : the multiethnic cohort. Cancer. 2016;122(9):1444–52.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Chang ET, Yang J, Alfaro-Velcamp T, So SK, Glaser SL, Gomez SL. Disparities in liver cancer incidence by birthplace, acculturation, and socioeconomic status in California Hispanics and Asians. Cancer Epidemiol Biomark Prev. 2010;19(12):3106–18.View ArticleGoogle Scholar
  24. Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual report to the nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312–37.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55.View ArticlePubMedGoogle Scholar
  26. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73. e1View ArticlePubMedPubMed CentralGoogle Scholar
  27. Makarova-Rusher OV, Altekruse SF, McNeel TS, Ulahannan S, Duffy AG, Graubard BI, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer. 2016;122(11):1757–65.View ArticlePubMedGoogle Scholar
  28. Vaeth PA, Caetano R, Rodriguez LA. The Hispanic Americans baseline alcohol survey (HABLAS): the association between acculturation, birthplace and alcohol consumption across Hispanic national groups. Addict Behav. 2012;37(9):1029–37.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013;108(8):1314–21.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Moore MS, Ivanina E, Bornschlegel K, Qiao B, Schymura MJ, Laraque F. Hepatocellular Carcinoma and Viral Hepatitis in New York City. Clinical Infectious Diseases. 2016;63(12):1577–83.Google Scholar
  31. Kuniholm MH, Jung M, Everhart JE, Cotler S, Heiss G, McQuillan G, et al. Prevalence of hepatitis C virus infection in US Hispanic/Latino adults: results from the NHANES 2007–2010 and HCHS/SOL studies. J Infect Dis. 2014;209(10):1585–90.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Ditah I, Ditah F, Devaki P, Ewelukwa O, Ditah C, Njei B, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and nutrition examination survey 2001 through 2010. J Hepatol. 2014;60(4):691–8.View ArticlePubMedGoogle Scholar
  33. Singh GK, Siahpush M, Hiatt RA, Timsina LR. Dramatic increases in obesity and overweight prevalence and body mass index among ethnic-immigrant and social class groups in the United States, 1976–2008. J Community Health. 2011;36(1):94–110.View ArticlePubMedGoogle Scholar
  34. Chow W, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245–57.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Li J, Weir HK, Jim MA, King SM, Wilson R, Master VA. Kidney cancer incidence and mortality among American Indians and Alaska Natives in the United States, 1990–2009. Am J Public Health. 2014;104(S3):S396–403.Google Scholar
  36. Espey DK, Wu X, Swan J, Wiggins C, Jim MA, Ward E, et al. Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska natives. Cancer. 2007;110(10):2119–52.View ArticlePubMedGoogle Scholar
  37. Wallace SP, Gutiérrez VF, Castañeda X. Access to preventive services for adults of Mexican origin. J Immigr Minor Health. 2008;10(4):363–71.View ArticlePubMedGoogle Scholar
  38. Martinsen RP, Morris CR, Pinheiro PS, Parikh-Patel A, Kizer KW. Colorectal Cancer Trends in California and the Need for Greater Screening of Hispanic Men. Am J Prev Med. 2016;51(6):e155–e163.Google Scholar
  39. Abraido-Lanza AF, Dohrenwend BP, Ng-Mak DS, Turner JB. The Latino mortality paradox: a test of the “salmon bias” and healthy migrant hypotheses. Am J Public Health. 1999;89(10):1543–8.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Turra CM, Elo IT. The impact of salmon bias on the Hispanic mortality advantage: new evidence from social security data. Popul Res Policy Rev. 2008;27(5):515–30.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Pinheiro PS. The influence of Hispanic ethnicity on nonsmall cell lung cancer histology and patient survival. Cancer. 2013;119(6):1285–6.View ArticlePubMedGoogle Scholar
  42. Pinheiro PS, Morris CR, Liu L, Bungum TJ, Altekruse SF. The impact of follow-up type and missed deaths on population-based cancer survival studies for Hispanics and Asians. J Natl Cancer Inst Monogr. 2014;2014(49):210–7.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Mariotto AB, Noone AM, Howlader N, et al. Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014;2014(49):145–86.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Fenelon A. Revisiting the Hispanic mortality advantage in the United States: the role of smoking. Soc Sci Med. 2013;82:1–9.View ArticlePubMedPubMed CentralGoogle Scholar
  45. UCLA Center for Health Policy Research. AskCHIS. Available at http://ask.chis.ucla.edu. Accessed 1 Aug 2016.

Copyright

© The Author(s). 2017